Terms: = Lung cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566
254 results:
1. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
;
Lancet Diabetes Endocrinol; 2024 May; 12(5):306-319. PubMed ID: 38554713
[TBL] [Abstract] [Full Text] [Related]
2. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
3. Catalase Expression Is an Independent Prognostic Marker in lung Adenocarcinoma.
Chen PM; Huang YH; Chen HH; Chu PY
Anticancer Res; 2024 Jan; 44(1):287-300. PubMed ID: 38159982
[TBL] [Abstract] [Full Text] [Related]
4. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell lung cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y; Kishimoto J; Sugawara S; Mizutani H; Daga H; Azuma K; Matsumoto H; Hataji O; Nishino K; Mori M; Shukuya T; Saito H; Tachihara M; Hayashi H; Tsuya A; Wakuda K; Yanagitani N; Sakamoto T; Miura S; Hata A; Okada M; Kozuki T; Sato Y; Harada T; Takayama K; Yamamoto N; Nakagawa K; Okamoto I
JAMA Oncol; 2024 Mar; 10(3):315-324. PubMed ID: 38127362
[TBL] [Abstract] [Full Text] [Related]
5. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
[TBL] [Abstract] [Full Text] [Related]
6. [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
Hao Y; Wu LN; Lyu YT; Liu YZ; Qin XS; Zheng R
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1827-1838. PubMed ID: 38008573
[No Abstract] [Full Text] [Related]
7. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
[TBL] [Abstract] [Full Text] [Related]
8. Surgery for stage IIB-IIIB small cell lung cancer.
Huang Z; Liu Y; Wang S; Ai K; Zhang P
World J Surg Oncol; 2023 Oct; 21(1):333. PubMed ID: 37872542
[TBL] [Abstract] [Full Text] [Related]
9. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H; de Marinis F; Dumoulin D; Reynolds C; Theelen WSME; Percent I; Gutierrez Calderon V; Johnson ML; Madroszyk-Flandin A; Garon EB; He K; Planchard D; Reck M; Popat S; Herbst RS; Leal TA; Shazer RL; Yan X; Harrigan R; Peters S;
Ann Oncol; 2024 Jan; 35(1):66-76. PubMed ID: 37866811
[TBL] [Abstract] [Full Text] [Related]
10. Incidence of mesothelioma in young people and causal exposure to asbestos in the Italian national mesothelioma registry (ReNaM).
Marinaccio A; Di Marzio D; Mensi C; Consonni D; Gioscia C; Migliore E; Genova C; Rossetto Giaccherino R; Eccher S; Murano S; Comiati V; Casotto V; Negro C; Mangone L; Miligi L; Piro S; Angelini A; Grappasonni I; Madeo G; Cozzi I; Ancona L; Staniscia T; Carrozza F; Cavone D; Vimercati L; Labianca M; Tallarigo F; Cascone G; Melis M; Bonafede M; Scarselli A; Binazzi A
Occup Environ Med; 2023 Nov; 80(11):603-609. PubMed ID: 37813485
[TBL] [Abstract] [Full Text] [Related]
11. Development and Validation of Prognostic Nomograms for lung Squamous Cell Carcinoma With Brain Metastasis in Patients Aged 45 Years or Older: A Population-Based Study.
Yang F; Gao L; Wang Q; Gao W
Cancer Control; 2023; 30():10732748231202953. PubMed ID: 37776257
[TBL] [Abstract] [Full Text] [Related]
12. Computed Tomography-derived intratumoral and peritumoral radiomics in predicting EGFR mutation in lung adenocarcinoma.
Shang Y; Chen W; Li G; Huang Y; Wang Y; Kui X; Li M; Zheng H; Zhao W; Liu J
Radiol Med; 2023 Dec; 128(12):1483-1496. PubMed ID: 37749461
[TBL] [Abstract] [Full Text] [Related]
13. lung immune prognostic index‑based nomogram for recurrence of hepatocellular carcinoma after postoperative adjuvant TACE.
Liang Y; Yang R; Shang J; Zhong D; Yang Q; Su Y; Shi Y; Huang X
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16461-16471. PubMed ID: 37707573
[TBL] [Abstract] [Full Text] [Related]
14. A predictive scoring model to select suitable patients for surgery on primary tumor in metastatic esophageal cancer.
Wei L; Xu J; Hu X; Xie Y; Lyu G
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1898. PubMed ID: 37702247
[TBL] [Abstract] [Full Text] [Related]
15. Real-World Progression-Free Survival as an Endpoint in lung cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
Mhatre SK; Machado RJM; Ton TGN; Trinh H; Mazieres J; Rittmeyer A; Bretscher MT
Clin Pharmacol Ther; 2023 Dec; 114(6):1313-1322. PubMed ID: 37696652
[TBL] [Abstract] [Full Text] [Related]
16. Lysosome-related genes: A new prognostic marker for lung adenocarcinoma.
Hu Z; Chen H; Li H; Xu S; Mu Y; Pan Q; Tong J; Xu G
Medicine (Baltimore); 2023 Sep; 102(35):e34844. PubMed ID: 37657029
[TBL] [Abstract] [Full Text] [Related]
17. Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell lung cancer Receiving Concurrent Chemoradiotherapy.
Simone CB; Serebrenik AA; Gore EM; Mohindra P; Brown SL; Wang D; Chetty IJ; Vujaskovic Z; Menon S; Thompson J; Fine G; Kaytor MD; Movsas B
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):404-414. PubMed ID: 37652301
[TBL] [Abstract] [Full Text] [Related]
18. Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S; Harutani Y; Tozuka T; Saito R; Koyama J; Sakamoto H; Sonoda T; Tsuchiya-Kawano Y; Oba T; Kudo K; Gyotoku H; Nakatomi K; Ariyasu R
Cancer Immunol Immunother; 2023 Nov; 72(11):3765-3772. PubMed ID: 37638979
[TBL] [Abstract] [Full Text] [Related]
19. Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver cancer and Chronic Liver Disease Mortality.
Zhao L; Zhang X; Coday M; Garcia DO; Li X; Mossavar-Rahmani Y; Naughton MJ; Lopez-Pentecost M; Saquib N; Shadyab AH; Simon MS; Snetselaar LG; Tabung FK; Tobias DK; VoPham T; McGlynn KA; Sesso HD; Giovannucci E; Manson JE; Hu FB; Tinker LF; Zhang X
JAMA; 2023 Aug; 330(6):537-546. PubMed ID: 37552302
[TBL] [Abstract] [Full Text] [Related]
20. Mediators of Black-White inequities in cardiovascular mortality among survivors of 18 cancers in the USA.
Sung H; Hyun N; Ohman RE; Yang EH; Siegel RL; Jemal A
Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 37471575
[TBL] [Abstract] [Full Text] [Related]
[Next]
